ORIGINAL COMMUNICATION

Journal of Neurology

, Volume 254, Issue 1, pp 26-28

First online:

Open Access This content is freely available online to anyone, anywhere at any time.

Does modafinil enhance activity of patients with myotonic dystrophy?

A double-blind placebo-controlled crossover study
  • A.R. WintzenAffiliated withDept. of Neurology and Clinical Neurophysiology, Leiden University Medical Centre, LUMC 9600 Email author 
  • , G.J. LammersAffiliated withDept. of Neurology and Clinical Neurophysiology, Leiden University Medical Centre, LUMC 9600
  • , J.G. van DijkAffiliated withDept. of Neurology and Clinical Neurophysiology, Leiden University Medical Centre, LUMC 9600

Abstract

We performed a double-blind placebo-controlled crossover study in 13 patients with myotonic dystrophy to address the question whether modafinil, known to improve hypersomnolence in myotonic dystrophy, may improve levels of activity as well. We used the Epworth Sleepiness Scale as a measure of hypersomnolence and a structured interview of the patient and the partner or housemate as a measure of activity. We additionally used a restricted form of the RAND-36 to relate a possible improvement of activity to perceived general health. We confirmed earlier positive findings of modafinil regarding reduced somnolence (p = 0.015), but no significant effects were seen regarding activity levels (p = 0.2 for patients’ self-reports and 0.5 for partners’ reports).

Keywords

myotonic dystrophy modafinil hypersomnolence levels of activity RAND-36